Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Accumulated Expenses (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Accumulated Expenses for 7 consecutive years, with $8.7 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 20.66% year-over-year to $8.7 million; the TTM value through Mar 2026 reached $8.7 million, up 20.66%, while the annual FY2025 figure was $6.2 million, 34.39% down from the prior year.
  • Accumulated Expenses hit $8.7 million in Q1 2026 for Barinthus Biotherapeutics, up from $6.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $11.9 million in Q3 2023 and bottomed at $9000.0 in Q2 2022.
  • Average Accumulated Expenses over 5 years is $7.1 million, with a median of $8.0 million recorded in 2024.
  • On a YoY basis, Accumulated Expenses climbed as much as 9335.83% in 2022 and fell as far as 92.24% in 2022.
  • Barinthus Biotherapeutics' Accumulated Expenses stood at $8.1 million in 2022, then increased by 14.28% to $9.2 million in 2023, then grew by 3.4% to $9.5 million in 2024, then tumbled by 34.39% to $6.2 million in 2025, then skyrocketed by 38.98% to $8.7 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $8.7 million, $6.2 million, and $6.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.